Phenylephrine Resinate Particles for Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current phenylephrine formulations require frequent administration, leading to fluctuations in therapeutic plasma levels and increased severity and frequency of side effects due to high peak plasma levels, necessitating the development of extended release formulations that can maintain effective levels for longer durations.
Innovation Solution
The development of extended release phenylephrine particles, specifically a drug-resin complex with cation polystyrene sulfonate coated with cellulose acetate and hydroxypropylcellulose, which provides sustained release of phenylephrine for 6 to 24 hours, allowing for less frequent dosing and combination with additional therapeutic agents like acetaminophen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate-release phenylephrine formulations are used, then rapid onset of action is achieved, but frequent administration is required leading to fluctuations in plasma levels and increased side effects
Solution Approach 1:
The phenylephrine dosage is segmented into multiple particle sizes (fine particles 0.5-2.0 mm and coarse particles 2.0-4.0 mm), where fine particles provide rapid onset and coarse particles provide sustained release, resolving the contradiction between fast onset and long duration
Solution Approach 2:
Phenylephrine is pre-coated onto starch particles with controlled pore structure before formulation, creating a reservoir that releases the drug gradually. This preliminary structuring enables sustained release without requiring frequent redosing
2Reliability
If immediate-release phenylephrine formulations are used, then effective plasma concentrations are achieved quickly, but high peak plasma levels cause increased severity and frequency of side effects
Solution Approach 1:
The formulation dynamically controls phenylephrine release through a two-phase system: an initial rapid release phase from fine particles to achieve therapeutic levels, followed by a sustained release phase from coarse particles to maintain levels without excessive peaks, thereby reducing side effects while maintaining efficacy
Solution Approach 2:
The release kinetics are modified by changing particle size distribution and coating properties, transforming the plasma concentration profile from sharp peaks to a more sustained, flattened curve that maintains therapeutic levels while reducing peak-related side effects
3Reliability
If frequent administration of phenylephrine is required, then therapeutic plasma levels are maintained, but patient compliance deteriorates
Solution Approach 1:
The formulation provides continuous phenylephrine release over an extended period (maintaining plasma levels for at least 8 hours), eliminating the need for frequent dosing and thereby improving patient compliance while maintaining reliable therapeutic levels
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The extended release formulation maintains phenylephrine plasma levels above 20-200 pg/mL for at least 6 to 24 hours, reducing side effects and improving patient compliance by allowing less frequent administration while matching the duration of action with other active ingredients.
Implementation Method 1
an extended release particle comprising a drug-resin complex comprising phenylephrine and a cation polystyrene sulfonate
Implementation Method 2
wherein said drug resin complex is coated with a coating, wherein said coating comprises cellulose acetate and hydroxypropylcellulose
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.